Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Final draft guidance: TA975

Final draft guidance (PDF 274 KB)

Committee papers (PDF 9.9 MB)

Public committee slides (PDF 1.14 MB)

Equality impact assessment (PDF 150 KB)

Final scope (PDF 230 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 252 KB)

Equality impact assessment (Scoping) (PDF 143 KB)

Final stakeholder list (PDF 170 KB)

Draft matrix post referral (PDF 170 KB)

Draft scope post referral (PDF 234 KB)

Final appraisal document (PDF 626 KB)

Committee papers (PDF 18.76 MB)

Public committee slides (PDF 1.66 MB)

Final appraisal document - Managed Access Agreement (PDF 573 KB)

Equality impact assessment (PDF 225 KB)

Final scope (PDF 293 KB)

Final stakeholder list (PDF 305 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 247 KB)

Equality impact assessment (Scoping) (PDF 179 KB)

Draft scope post referral (PDF 350 KB)

Draft matrix post referral (PDF 305 KB)